About this trial
This randomized controlled trial compares two techniques for eyelid retraction during intravitreal injection (IVI) of anti-VEGF agents: the standard wire eyelid speculum (Group A) versus cotton-tipped applicator retraction (Group B) in patients with neovascular AMD, diabetic macular edema, or retinal vein occlusion.
The study evaluates four outcomes: (1) patient pain perception measured by a 10-cm visual analogue scale immediately after injection; (2) procedure duration from retraction device placement to removal; (3) patient satisfaction assessed by a 5-item Likert scale; and (4) safety including rates of subconjunctival hemorrhage, corneal abrasion, endophthalmitis, and intraocular pressure elevation.
A novel syringe cap technique using the Terumo 31G insulin syringe plastic cap as an injection-site marker (3.5 mm for pseudophakic eyes, 5.0 mm for phakic eyes from the limbus) is employed in both groups, replacing the traditional caliper.
Randomization is stratified by diagnosis and prior injection history using permuted block randomization (block sizes 4 and 6). The target sample size is 120 patients (60 per group) at Walailak University Hospital, Nakhon Si Thammarat, Thailand.
Eligibility criteria
Qualifiers
Age 18 years or older
Diagnosed with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or retinal vein occlusion (RVO)
Scheduled for intravitreal anti-VEGF injection (bevacizumab, aflibercept, or faricimab)
Able to provide written informed consent
Disqualifiers
Active ocular infection or inflammation
Known allergy to povidone-iodine, tetracaine, or levofloxacin
Inability to cooperate with the injection procedure
Concurrent participation in another interventional clinical trial
Trial design
Treatments tested in this trial
- Eyelid Speculum Retraction
- Cotton-Tipped Applicator Retraction
Treatment groups
Locations
Sponsors and collaborators
Jakkrit Juhong
Lead sponsor
Walailak University
Sponsor institution